No connection

Search Results

PLUR vs RADX

PLUR
Pluri Inc.
BEARISH
Price
$3.51
Market Cap
$35.3M
Sector
Healthcare
AI Confidence
95%
RADX
Radiopharm Theranostics Limited
BEARISH
Price
$4.58
Market Cap
$36.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
PLUR
--
RADX
--
Forward P/E
PLUR
-1.85
RADX
-1.75
P/B Ratio
PLUR
-2.4
RADX
1.43
P/S Ratio
PLUR
26.35
RADX
2.22
EV/EBITDA
PLUR
-2.58
RADX
-413.38

Profitability

Gross Margin
PLUR
40.63%
RADX
-136.51%
Operating Margin
PLUR
-3285.86%
RADX
-423.75%
Profit Margin
PLUR
0.0%
RADX
-286.16%
ROE
PLUR
--
RADX
-92.1%
ROA
PLUR
-50.6%
RADX
-28.33%

Growth

Revenue Growth
PLUR
7.0%
RADX
154.5%
Earnings Growth
PLUR
--
RADX
--

Financial Health

Debt/Equity
PLUR
--
RADX
--
Current Ratio
PLUR
0.43
RADX
3.01
Quick Ratio
PLUR
0.39
RADX
3.0

Dividends

Dividend Yield
PLUR
--
RADX
--
Payout Ratio
PLUR
0.0%
RADX
0.0%

AI Verdict

PLUR BEARISH

PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.

Strengths
Recent quarterly earnings beats (3 of last 4 quarters)
Positive YoY EPS growth (+71%)
Gross margin remains positive at 40.63%
Risks
Negative equity (P/B -2.40) indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.43)
Catastrophic operating losses (-3285.86% margin)
RADX BEARISH

RADX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation benchmarks like the Graham Number due to negative earnings. While the company shows impressive YoY revenue growth of 154.50% and maintains strong short-term liquidity (Current Ratio 3.01), these are overshadowed by a catastrophic negative gross margin of -136.51%. The stock is in a severe technical downtrend, having collapsed from a 52-week high of $16.25 to $4.58, suggesting a significant loss of investor confidence despite optimistic analyst price targets.

Strengths
Exceptional YoY revenue growth of 154.50%
Strong liquidity position with a Current Ratio of 3.01
Low Price-to-Sales ratio (2.22) relative to biotech peers
Risks
Negative gross margins indicate the cost of producing goods exceeds revenue
Severe operating losses with an operating margin of -423.75%
Extreme technical weakness (Technical Trend score 0/100)

Compare Another Pair

PLUR vs RADX: Head-to-Head Comparison

This page compares Pluri Inc. (PLUR) and Radiopharm Theranostics Limited (RADX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile